Rebecca Weil

Corporate Officer/Principal bei OCULIS HOLDING AG

Health Technology

Finance

Consumer Services

Aktive Positionen von Rebecca Weil

Unternehmen	Position	Beginn	Ende
OCULIS HOLDING AG	Corporate Officer/Principal	11.09.2023	-

Unternehmen	Position	Beginn	Ende
IDORSIA LTD	Vertrieb & Marketing	01.07.2019	01.08.2023
SHIRE	Corporate Officer/Principal	01.08.2016	01.03.2019
Juvenile Diabetes Research Foundation (New York)	Direktor/Vorstandsmitglied	-	-
BAUSCH + LOMB CORPORATION	Vertrieb & Marketing	-	-
NOVARTIS AG	Corporate Officer/Principal	-	-
ALCON INC.	Corporate Officer/Principal	-	-

Massachusetts Institute of Technology	Doctorate Degree
Princeton University	Undergraduate Degree

International

Operativ

Corporate Officer/Principal	4
Sales & Marketing	2
Doctorate Degree	1

Sektoral

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	5
OCULIS HOLDING AG	Health Technology
IDORSIA LTD	Health Technology
ALCON INC.	Health Technology
NOVARTIS AG	Health Technology
BAUSCH + LOMB CORPORATION	Health Technology

Private Unternehmen	2
Shire Plc Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland.	Health Technology
Juvenile Diabetes Research Foundation (New York)

Private Unternehmen

Health Technology

Juvenile Diabetes Research Foundation (New York)